A trial to examine the effects of lobeglitazone, on changes in Bone mineral density over 52-weeks of treatment compared to placebo in Korean patients with type 2 diabetes

Trial Profile

A trial to examine the effects of lobeglitazone, on changes in Bone mineral density over 52-weeks of treatment compared to placebo in Korean patients with type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Lobeglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2016 New trial record
    • 17 Apr 2016 Results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top